BPC-157 is a synthetic fifteen-residue peptide described as a partial sequence of body protection compound found in gastric juice. It is studied in preclinical angiogenesis and tissue-repair models and is supplied strictly for laboratory research.

What mechanisms does the BPC-157 literature describe?

Published preclinical work centres on VEGFR2-Akt-eNOS angiogenic signalling, modulation of nitric oxide pathways, and growth hormone receptor expression in fibroblast models, alongside a large body of rodent gastrointestinal cytoprotection studies.

How should BPC-157 be stored?

Lyophilized material is kept at -20°C protected from light. Reconstituted solutions in bacteriostatic diluent are conventionally refrigerated and used within about four weeks; preservative-free solutions are aliquoted and frozen.

Compound overviews · 7 min read

BPC-157: what the research literature describes

Sequence origin, the angiogenic and cytoprotective pathways reported in preclinical models, stability characteristics, and where the evidence base currently stops.

Origin and structure

BPC-157 is a synthetic pentadecapeptide — fifteen residues, sequence GEPPPGKPADDAGLV — described as a partial sequence of body protection compound isolated from gastric juice. It is unmodified: no terminal acetylation, no amidation, no non-natural residues, with a molecular weight of approximately 1419 Da.

That structural simplicity is relevant to handling. Without stabilising modifications the peptide relies on its proline-rich composition for resistance to enzymatic degradation, and it is notably stable in acidic conditions relative to most short peptides of comparable length.

Pathways reported in preclinical work

The published preclinical literature centres on angiogenic signalling. Reported observations include upregulation of VEGFR2 expression and activation of the VEGFR2-Akt-eNOS pathway in endothelial cell models, with associated increases in tubule formation in vitro.

A second reported strand concerns interaction with the nitric oxide system, where the compound has been described as modulating NO release in both directions depending on baseline state, and a third concerns growth hormone receptor expression in tendon fibroblast models. Cytoprotective effects on gastric and intestinal mucosa in rodent injury models constitute the largest single body of published work.

Where the evidence stops

Essentially all of the above is rodent and in vitro work. Human clinical evidence is minimal, and the compound has not been evaluated by regulatory agencies for safety or efficacy in any indication. Reviews in the area consistently note methodological heterogeneity across the rodent literature and a concentration of publication within a small number of research groups.

For laboratory purposes this means BPC-157 is best treated as a mechanistically interesting research tool with a substantial but narrow evidence base — not as a characterised agent with established translational relevance.

Practical handling

Lyophilized material is stable at -20°C protected from light and tolerates ambient shipping windows well. Reconstituted in bacteriostatic water and refrigerated, solutions are conventionally used within about four weeks; in preservative-free diluent, aliquot and freeze.

The peptide dissolves readily in neutral aqueous diluent without acid assistance. It is frequently studied alongside TB-500 in tissue-repair models, which is why the two appear together in most combination research preparations.

Frequently asked questions

What is BPC-157?: BPC-157 is a synthetic fifteen-residue peptide described as a partial sequence of body protection compound found in gastric juice. It is studied in preclinical angiogenesis and tissue-repair models and is supplied strictly for laboratory research.
What mechanisms does the BPC-157 literature describe?: Published preclinical work centres on VEGFR2-Akt-eNOS angiogenic signalling, modulation of nitric oxide pathways, and growth hormone receptor expression in fibroblast models, alongside a large body of rodent gastrointestinal cytoprotection studies.
How should BPC-157 be stored?: Lyophilized material is kept at -20°C protected from light. Reconstituted solutions in bacteriostatic diluent are conventionally refrigerated and used within about four weeks; preservative-free solutions are aliquoted and frozen.